Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism
Authors
Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
Mark R. Burns (ORCID: https://orcid.org/0000-0002-2810-267X)
Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
Anthony W. Tolcher (ORCID: https://orcid.org/0000-0002-6322-9721)
Andrae Vandross
Institutions
The University of Texas MD Anderson Cancer Center (US)
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism
Sarina A. Piha‐Paul, Mark R. Burns, Alexander I. Spira, Anthony W. Tolcher et al.
Citations
1 citations
Journal
ESMO Open
Topics
Polyamine Metabolism and Applications
Field-Weighted Citation Impact (FWCI)
0.81
article
Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism
Sarina A. Piha‐Paul, Mark R. Burns, Alexander I. Spira, Anthony W. Tolcher, Andrae Vandross
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
ESMO OpenVol. 10(9)
Institutions
The University of Texas MD Anderson Cancer Center (US), Nexen (Canada) (CA), Fairfax Neonatal Associates (US), Aminex Therapeutics (United States) (US)